Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421525 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of hLL1 in Multiple Myeloma
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00421525 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 25 participants.
The verdict
NCT00421525, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who have failed at least two prior standard systemic treatments.
Interventions
- BIOLOGICAL milatuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421525
The ClinicalTrials.gov registry entry for NCT00421525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which milatuzumab is the first listed.
NCT00421525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00421525 about?
NCT00421525 is a clinical study titled "Phase I/II Study of hLL1 in Multiple Myeloma". This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who have failed at least two prior standard systemic treatments.
What is the current status of trial NCT00421525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00421525?
The interventions under investigation include: milatuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00421525?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.